Uniqure NV
QURE25.650USD
+1.130+4.61%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
1.59BValor de mercado
PerdaP/L TTM
Mais detalhes de Uniqure NV Empresa
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Informações de Uniqure NV
Código da empresaQURE
Nome da EmpresaUniqure NV
Data de listagemFeb 05, 2014
CEOKapusta (Matthew)
Número de funcionários209
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
EndereçoPaasheuvelweg 25a
CidadeAMSTERDAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1105 BP
Telefone31202406000
Sitehttps://www.uniqure.com/
Código da empresaQURE
Data de listagemFeb 05, 2014
CEOKapusta (Matthew)
Executivos da empresa Uniqure NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-1466.00%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+5858.00%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+5858.00%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
24.26K
-7803.00%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+5858.00%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+5858.00%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-4670.00%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
--
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-1466.00%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+5858.00%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+5858.00%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
24.26K
-7803.00%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+5858.00%
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: há 2 horas
Atualizado em: há 2 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
5.91%
Outro
64.55%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.90%
Avoro Capital Advisors LLC
7.13%
RTW Investments L.P.
7.10%
EcoR1 Capital, LLC
6.40%
abrdn Inc.
5.91%
Outro
64.55%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
41.44%
Investment Advisor
27.89%
Hedge Fund
19.42%
Corporation
3.83%
Research Firm
3.16%
Venture Capital
1.48%
Individual Investor
1.47%
Pension Fund
0.91%
Private Equity
0.89%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
422
59.36M
95.29%
-2.44M
2025Q3
368
55.15M
89.53%
-7.50M
2025Q2
396
55.26M
101.06%
-1.58M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
5.55M
8.9%
+4.74M
+591.04%
Sep 30, 2025
Avoro Capital Advisors LLC
4.44M
7.13%
+819.44K
+22.61%
Sep 30, 2025
RTW Investments L.P.
4.42M
7.1%
-733.26K
-14.22%
Sep 30, 2025
EcoR1 Capital, LLC
3.99M
6.4%
--
--
Sep 30, 2025
abrdn Inc.
2.94M
4.72%
+189.03K
+6.87%
Sep 30, 2025
Bristol Myers Squibb
2.39M
3.83%
--
--
Sep 30, 2024
Franklin Advisers, Inc.
1.98M
3.17%
+369.97K
+23.05%
Sep 30, 2025
State Street Investment Management (US)
1.44M
2.32%
+301.20K
+26.36%
Sep 30, 2025
Jennison Associates LLC
999.48K
1.6%
+859.42K
+613.61%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
2.12%
+68.87K
+5.49%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Global X Genomics & Biotechnology ETF
3.77%
WisdomTree BioRevolution Fund
3.51%
Virtus LifeSci Biotech Clinical Trials ETF
2.87%
Invesco NASDAQ Future Gen 200 ETF
2.23%
Alger Mid Cap 40 ETF
2.06%
State Street SPDR S&P Biotech ETF
1.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.84%
ProShares Ultra Nasdaq Biotechnology
0.36%
Invesco Nasdaq Biotechnology ETF
0.36%
Franklin Genomic Advancements ETF
0.34%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção3.77%
WisdomTree BioRevolution Fund
Proporção3.51%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção2.87%
Invesco NASDAQ Future Gen 200 ETF
Proporção2.23%
Alger Mid Cap 40 ETF
Proporção2.06%
State Street SPDR S&P Biotech ETF
Proporção1.37%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.84%
ProShares Ultra Nasdaq Biotechnology
Proporção0.36%
Invesco Nasdaq Biotechnology ETF
Proporção0.36%
Franklin Genomic Advancements ETF
Proporção0.34%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
